YOKNE'AM ILLIT, Israel, June 5, 2024
/PRNewswire/ -- Lumenis Be. Ltd., a leading energy-based
medical device company for aesthetic and eye care solutions, is
proud to announce the launch of its breakthrough laser system
designed to combat hair loss. Recently cleared by the Food and Drug
Administration (FDA), FoLix becomes the first and only fractional
laser choice for safe, effective, and natural hair loss treatment
for women and men in the United
States[1].
Affecting more than 85% of men and 50% of women[2],
hair loss remains a persistent, widespread challenge. FoLix's
groundbreaking approach utilizes fractional laser and Lumenis'
proprietary technology tailored for hair. This is a revolution
for hair loss patients, offering results in 4-6 monthly
sessions with no chemicals, needles, anesthesia, surgery,
or downtime.
FoLix's unique technology delivers precise pulses of laser that
leverage the body's natural processes to stimulate hair follicles.
Lumenis' pre-clinical and clinical studies measuring the laser's
effect showed a positive impact on hair growth, with noticeable
improvements in scalp hair appearance and an increase in hair
count[3]. "Fractional lasers have been shown to have
remarkable effects on the skin and now, finally, Lumenis has been
able to harness that power and bring an innovative solution for
hair stimulation," said Dr. Marc
Avram, a renowned hair transplant specialist and Clinical
Professor of Dermatology at Weill Cornell Medical College
(WCMC).
"With hair loss becoming a growing concern, FoLix emerges as a
pivotal innovation for both patients and providers," adds Dr.
Neil Sadick, a world-leading
dermatologist and researcher, and Clinical Professor of Dermatology
at WCMC. "FoLix offers a unique opportunity to help those suffering
from hair loss through short monthly sessions and with minimal
discomfort and no downtime."
"At Lumenis, we're committed to transforming lives through
science and innovation. FoLix is about more than just hair; it's
about having the self-confidence to live life to the fullest," said
Lumenis CEO Tzipi Ozer-Armon. "We
are eager to collaborate with providers across the US to extend the
influence and accessibility of this groundbreaking solution."
For more information about FoLix please visit
Lumenis.com/FoLix.
About Lumenis
Lumenis is a global leader in the medical aesthetic market and
is a world-renowned expert in developing and commercializing
innovative energy-based technologies, including Laser, Intense
Pulsed Light (IPL) and Radiofrequency (RF). For more than 50 years,
Lumenis' ground-breaking products have redefined medical treatments
and set technological and clinical gold-standards, revolutionizing
existing treatment methods, and creating solutions for previously
untreatable conditions. Lumenis is a portfolio company of EQT
Private Capital Asia. For more information regarding Lumenis' range
of clinical solutions, please visit: www.lumenis.com.
About FoLix
FoLix is a non-ablative fractional laser device to improve the
appearance of scalp hair in adult males and females with
Fitzpatrick skin types I to IV, who are seeking treatment for hair
loss.
FoLix treatment could cause redness, swelling, scarring, and
pigmentation change. The use of FoLix is contraindicated for
patients with any concurrent cancer or history of skin cancer,
active infection, fungal or bacterial diseases. See the system user
manual for a complete list of contraindications and risks.
*The physicians' testimonials represent a specific experience of
a paid spokesperson. Experience of others may vary.
1. See the "About FoLix" section for the indication
of use and relevant skin types.
2. Men's Hair Loss, American Hair Loss
Association, https://www.americanhairloss.org/mens-hair-loss/;
Hair Loss in Women, Cleveland Clinic,
https://my.clevelandclinic.org/health/diseases/16921-hair-loss-in-women.
3. As measured in 1-month and 3-month follow-ups
following the last treatment session, compared to baseline. Data on
file.
Photo:
https://mma.prnewswire.com/media/2430951/Lumenis_Be.jpg
Logo -
https://mma.prnewswire.com/media/2431035/FoLix_by_Lumenis_Logo.jpg
Contact:
Shani Peles
shani.peles@lumenis.com
+972 525974552
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lumenis-introduces-folix-the-first-fda-cleared-proprietary-fractional-laser-for-hair-loss-treatment-302164738.html
SOURCE Lumenis Be Ltd.